- Home
- JELD vs KZIA Comparison
JELD vs KZIA Comparison
Compare JELD & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | KZIA |
|---|---|---|
| Founded | 1960 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.8M | 93.2M |
| IPO Year | 2016 | 2002 |
Fundamental Metrics
Financial Performance| Metric | JELD | KZIA |
|---|---|---|
| Price | $1.54 | $8.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.43 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 1.6M | 201.8K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $0.64 |
| 52 Week High | $6.98 | $17.40 |
Technical Indicators
Market Signals| Indicator | JELD | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 26.92 | 54.36 |
| Support Level | N/A | $7.54 |
| Resistance Level | $2.06 | $8.17 |
| Average True Range (ATR) | 0.15 | 1.09 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 4.71 | 49.69 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.